The Efficacy Of The Preserflo Implant In Primary Open-Angle Glaucoma With Follow-Up Extended To Six Months.

To evaluate the efficacy of the Preserflo implant in reducing intraocular pressure (IOP) and decreasing hypotensive drug dependence in patients with mild-to-moderate stage primary open-angle glaucoma who have significant visual progression.

Complejo Hospitalario Universitario de Canarías

A prospective non-randomised study was conducted at the Complejo Hospitalario Universitario de Canarias between June 2023 and September 2024. Fifty patients diagnosed with primary open-angle glaucoma, classified as mild to moderate according to the Disc Damage Likelihood Scale (DDLS) and with confirmed visual progression in the last three fields evaluated were included. All subjects underwent implantation of the Preserflo, a device intended to drain the anterior chamber. Key parameters were assessed, including IOP by Goldman tonometry, perimetry performed with the Octopus system and the number of antihypertensive medications used before and after the procedure, with follow-up extended to six months.

Mean baseline IOP was 21.56 ± 5.63 mmHg. At 24 hours post-implantation it was reduced to 7.58 ± 5.85 mmHg, maintained at 8.85 ± 4.55 mmHg at one week, 10.87 ± 3.81 mmHg at one month, 11.50 ± 3.03 mmHg at three months and 12.03 ± 2.53 mmHg at six months. The mean number of antihypertensive medications decreased from 2.22 ± 0.44 initially to 0.36 ± 0.56 at six months.

The Preserflo implant achieved a significant reduction in IOP, lowering it by 59% at seven days and maintaining a 47% reduction at six months. In addition, an 85% decrease in hypotensive drug dependence was observed in patients with mild-to-moderate primary open-angle glaucoma.